These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35468260)

  • 61. The Harada score in the US population of children with Kawasaki disease.
    Tewelde H; Yoon J; Van Ittersum W; Worley S; Preminger T; Goldfarb J
    Hosp Pediatr; 2014 Jul; 4(4):233-8. PubMed ID: 24986993
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y; Mori M; Hara T; Inaba A; Oba MS; Yokota S
    Ther Apher Dial; 2015 Apr; 19(2):171-7. PubMed ID: 25257673
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical Features of Kawasaki Disease With Atlantoaxial Rotatory Fixation.
    Michihata N; Suzuki T; Honda A; Oka I; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Pediatr Infect Dis J; 2022 Aug; 41(8):626-630. PubMed ID: 35544743
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease.
    Yellen ES; Gauvreau K; Takahashi M; Burns JC; Shulman S; Baker AL; Innocentini N; Zambetti C; Pancheri JM; Ostrow A; Frazer JR; Sundel RP; Fulton DR; Newburger JW
    Pediatrics; 2010 Feb; 125(2):e234-41. PubMed ID: 20100771
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
    Wu Y; Liu FF; Xu Y; Wang JJ; Samadli S; Wu YF; Liu HH; Chen WX; Luo HH; Zhang DD; Wei W; Hu P
    Clin Exp Med; 2019 May; 19(2):173-181. PubMed ID: 30617865
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The role of corticosteroids in the treatment of Kawasaki disease.
    Chang LS; Kuo HC
    Expert Rev Anti Infect Ther; 2020 Feb; 18(2):155-164. PubMed ID: 31914832
    [No Abstract]   [Full Text] [Related]  

  • 67. Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease.
    Migally K; Braunlin EA; Zhang L; Binstadt BA
    Pediatr Res; 2018 Jun; 83(6):1136-1145. PubMed ID: 29554081
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
    Wei M; Huang M; Chen S; Huang G; Huang M; Qiu D; Guo Z; Jiang J; Zhou X; Yu Q; Guo Y; Fu L; Gao W; Li F
    Pediatr Cardiol; 2015 Aug; 36(6):1166-72. PubMed ID: 25812827
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature.
    Athappan G; Gale S; Ponniah T
    Cardiovasc J Afr; 2009; 20(4):233-6. PubMed ID: 19701534
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Kawasaki disease shock syndrome: Unique and severe subtype of Kawasaki disease.
    Gamez-Gonzalez LB; Moribe-Quintero I; Cisneros-Castolo M; Varela-Ortiz J; Muñoz-Ramírez M; Garrido-García M; Yamazaki-Nakashimada M
    Pediatr Int; 2018 Sep; 60(9):781-790. PubMed ID: 29888440
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
    Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Predicting IVIG resistance in UK Kawasaki disease.
    Davies S; Sutton N; Blackstock S; Gormley S; Hoggart CJ; Levin M; Herberg JA
    Arch Dis Child; 2015 Apr; 100(4):366-8. PubMed ID: 25670405
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The relationship between TNF-like protein 1A and coronary artery aneurysms in children with Kawasaki disease.
    Zhang J; Weng H; Pei Q; Yang P; Fan W; Liu R; Yi Q
    Clin Exp Med; 2022 Feb; 22(1):57-63. PubMed ID: 34232416
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Seasonal Variation in Epidemiology of Kawasaki Disease-Related Coronary Artery Abnormalities in Japan, 1999-2017.
    Kitano N; Takeuchi T; Suenaga T; Kakimoto N; Naka A; Shibuta S; Tachibana S; Takekoshi N; Suzuki T; Tsuchihashi T; Yamano T; Akasaka T; Suzuki H
    J Epidemiol; 2021 Feb; 31(2):132-138. PubMed ID: 32092750
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Low risk of treatment resistance in Down syndrome with Kawasaki disease.
    Takatsuki S; Ogata S; Ishii M; Yokozawa M; Ono M; Fujiwara M; Ida H; Motomura H; Moriuchi H; Taketazu M; Kawamura Y; Kawano T; Izumi T; Shiono J; Tsuchiya S; Tsuchiya K; Goushi T; Ichida F; Saji T
    Pediatr Int; 2017 Dec; 59(12):1236-1239. PubMed ID: 28960680
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Corticosteroid treatment of refractory Kawasaki disease.
    Lang BA; Yeung RS; Oen KG; Malleson PN; Huber AM; Riley M; Ebbeson R; Ramsey SE; Laxer RM; Silverman ED; McCrindle BW; Ratnapalan S; Feldman BM
    J Rheumatol; 2006 Apr; 33(4):803-9. PubMed ID: 16583481
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Epidemiology and Risk Factors for Giant Coronary Artery Aneurysms Identified After Acute Kawasaki Disease.
    Masuda H; Ae R; Koshimizu TA; Matsumura M; Kosami K; Hayashida K; Makino N; Matsubara Y; Sasahara T; Nakamura Y
    Pediatr Cardiol; 2021 Apr; 42(4):969-977. PubMed ID: 33682062
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
    Hashino K; Ishii M; Iemura M; Akagi T; Kato H
    Pediatr Int; 2001 Jun; 43(3):211-7. PubMed ID: 11380911
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Kawasaki disease: clinical spectrum of 88 patients in a high-prevalence African-American population.
    Marquez J; Gedalia O; Candia L; Ranjit K; Hescock GC; Espinoza LR; Stopa AR; Gedalia A
    J Natl Med Assoc; 2008 Jan; 100(1):28-32. PubMed ID: 18277805
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease.
    Cha S; Yoon M; Ahn Y; Han M; Yoon KL
    J Korean Med Sci; 2008 Aug; 23(4):718-22. PubMed ID: 18756064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.